Baseline characteristics of eligible patients (N = 38)
| . | Disease type . | |||||
|---|---|---|---|---|---|---|
| sAML . | AML . | CMML . | ALL . | CML . | MDS . | |
| No. of patients | 18 | 10 | 4 | 3 | 2 | 1 |
| Median no. of prior Rx (range) | 2 (1-4) | 2 (1-3) | 1 (1-2) | 2 (1-3) | 3 and 6 | 1 |
| JAK2V617F+ | 7 | 3 | 2 | 0 | 0 | 0 |
| Karyotype | ||||||
| Diploid | 6 | 5 | 3 | 1 | — | 1 |
| Del (5) | 1 | 1 | — | — | — | — |
| Del (7) | 7 | — | — | — | — | — |
| Del (20) | — | — | 1 | — | — | — |
| t (6;11) | — | 1 | — | — | — | — |
| t (8;21) | 1 | — | — | — | — | — |
| t (9;22) | — | — | — | 1 | 2 | — |
| inv (9) | — | — | — | 1 | — | — |
| Other | 3 | 3 | — | — | — | — |
| Splenomegaly | 6* | — | 2† | — | — | — |
| . | Disease type . | |||||
|---|---|---|---|---|---|---|
| sAML . | AML . | CMML . | ALL . | CML . | MDS . | |
| No. of patients | 18 | 10 | 4 | 3 | 2 | 1 |
| Median no. of prior Rx (range) | 2 (1-4) | 2 (1-3) | 1 (1-2) | 2 (1-3) | 3 and 6 | 1 |
| JAK2V617F+ | 7 | 3 | 2 | 0 | 0 | 0 |
| Karyotype | ||||||
| Diploid | 6 | 5 | 3 | 1 | — | 1 |
| Del (5) | 1 | 1 | — | — | — | — |
| Del (7) | 7 | — | — | — | — | — |
| Del (20) | — | — | 1 | — | — | — |
| t (6;11) | — | 1 | — | — | — | — |
| t (8;21) | 1 | — | — | — | — | — |
| t (9;22) | — | — | — | 1 | 2 | — |
| inv (9) | — | — | — | 1 | — | — |
| Other | 3 | 3 | — | — | — | — |
| Splenomegaly | 6* | — | 2† | — | — | — |
AML indicates acute myeloid leukemia; MPN, myeloproliferative neoplasm; sAML, secondary AML (post-MPN AML); CMML, chronic myelomonocytic leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelocytic leukemia; MDS, myelodysplastic syndrome; Rx, therapy; and —, not seen.
Two patients in this group had splenectomy before therapy.
One patient in this group had splenectomy before therapy.